<h4>Background</h4>NTRK fusions are relatively rare in papillary thyroid carcinoma (PTC), and their clinicopathological characteristics, particularly in unselected populations and in comparison with BRAF<sup>V600E</sup> PTC, have not been systematically elucidated.<h4>Methods</h4>In this retrospective study, we analyzed PTC patients who underwent surgery between October 2022 and May 2025. The gene discussed is BRAF; the disease is differentiated thyroid carcinoma.